stockrowExelixis, Inc. (EXEL) vs Halozyme Therapeutics, Inc. (HALO)
- Exelixis, Inc. EXEL 69.50 +1.15%
- Halozyme Therapeutics, Inc. HALO 103.78 −15.60%
Exelixis, Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. Exelixis, Inc. is the larger, with a market value of $16.8B against $14.0B — 1.2× the size. Exelixis, Inc. trades at the lower P/E: 19.9× against 29.5×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 45.0% against 9.12%. Exelixis, Inc. has the higher net margin (35.5% vs 26.9%) and the higher return on invested capital (66.6% vs 19.9%). Across the 21 metrics below, Exelixis, Inc. leads on 15 and Halozyme Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | EXEL | HALO | Biotechnology median |
|---|---|---|---|
| Gross margin | 96.26% | 82.27% | 65.16% |
| Operating margin | 40.19% | 37.41% | 0.00% |
| Net margin | 35.45% | 26.93% | 0.00% |
| Free cash flow margin | 45.84% | 49.84% | 0.00% |
| Return on equity | 44.32% | 216.38% | (50.12%) |
| Return on assets | 33.17% | 17.05% | (45.60%) |
| Return on invested capital | 66.59% | 19.87% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack